Company Logo IPR in Successful University - Industry Collaborations

Cengiz A Tarhan

Managing Director UCL Business PLC

O ve r v i e w

 UCL  Enterprise at UCL – role of UCLB  Why we collaborate  Recent examples  Summary

 Established over 180 years ago  First university in England to  admit students of any race, class or religion,  welcome women on equal terms  teach experimental science, modern European languages, Laws…  Today – over 4000 researchers and  Ranked 5th in the QS World University rankings for 2014 and 20th Academic Ranking of World Universities - 2014 ( 3rd in Europe) in the  Exceptional strength in BioMedicine

O ve r v i e w

“UCL ranked the leading institution in the UK as a partner for industry in the biotechnology and pharmaceutical sectors” May 2013

E nte r p r i s e at U C L i s e vo l v i n g

W hy we c o l l a b o rate w i t h I n d u st r y

    It makes sense Best universities and best companies do Symbiotic relationship – should be two way Helps achieve our mission to make IMPACT But;      Pick your partners well Protect your reputation Remain flexible on terms Document the arrangement Manage the relationship

E x a m p l e s o f c o l l a b o r a t i o n w i t h I n d u s t r y a t U C L

 Direct      Studentships – beware of IP leakage Consultancy – IP rights defined within agreement Contract research – usually IP vested in company Collaborative research – complex IP negotiation Strategic partnerships – multiple programs  Indirect   Through UCL’s spin out companies Through our partner hospitals

W h e n I P i s I nvo l ve d

 Overvaluing IP  Undervaluing IP  Warranties and indemnities  Access to Background IP  Licensing versus assigning  Ownership of Arising/Foreground IP  Money – costs/upfront/milestones/royalties  Termination – what happens to IP  And more!

Recent examples of collaborative research at UCL

 Eisai – drug discovery alliance  Pfizer – collaboration on stem cell- based technology  Novozymes BioPharma – combining technology platforms  Cell Therapy Catapult – treatment for leukaemia  Novo Nordisk – mapping diabetes  Takeda – tackling muscle disorders and muscular dystrophy

U n l o c k i n g the potential of C a r b o n N a n o t u b e s

Most high tech displays and touchscreens are made of transparent conductive film which requires Indium Tin Oxide (ITO)  Costs of processing ITO are high and screens tend to be brittle – not suitable for flexible displays.  Collaboration with Linde is based on developing a solution to use Single walled carbon nanotubes (SWCN) as an alternative.

U n l o c k i n g the potential of C a r b o n N a n o t u b e s

 Researchers at UCL identified a way of purifying the SWCN’s to make them useful for new generation flexible screens.

U n l o c k i n g the potential of C a r b o n N a n o t u b e s

 Patent protection secured  Licence to Linde Group in 2011  Linde Nanomaterials formed in 2012 with manufacturing facility in San Marcos, California  SEER e Ink launched in 2013  Potential highlighted in Touch Display Research Inc., ITO replacement report, May 2014) estimating non ITO transparent conducting films market is likely to be worth $8.1billion by 2021

S u m m a r y

 UCL is committed to Enterprise to deliver IMPACT  Engagement with Industry is crucial  IPR plays an important role  It’s a relationship with ‘ups and downs’  Successful relationship needs to be ‘managed’